Altered Bone Mass and Turnover in Female Patients with Adrenal Incidentaloma: The Effect of Subclinical Hypercortisolism
M. Torlontano1,
I. Chiodini1,
M. Pileri,
G. Guglielmi,
M. Cammisa,
S. Modoni,
V. Carnevale,
V. Trischitta and
A. Scillitani
Division and Research Unit of Endocrinology (M.T., I.C., V.T.,
A.S.), Departments of Clinical Laboratory (M.P.), Radiology (G.G.,
M.C.), Nuclear Medicine (S.M.), and Internal Medicine (V.C.),
Scientific Institute Casa Sollievo della Sofferenza, 71013 S. Giovanni
Rotondo (FG), Italy
Address all correspondence and requests for reprints to: Massimo Torlontano, M.D., Division and Research Unit of Endocrinology, Scientific Institute Casa Sollievo della Sofferenza, 71013 S. Giovanni Rotondo (FG), Italy.
The strategy of treatment for patients with adrenal incidentalomas(AI)
may depend upon the presence of hormonal hypersecretion.Although
alterations of bone turnover have been recently reported,data on bone
mineral density (BMD) are not available in AI patients.We evaluated
bone turnover and BMD in 32 female AI patientsand 64 matched controls.
Spinal and femoral BMD were similarin patients and controls. Serum
bone GLA protein (6.8 ±3.5 vs. 8.8 ± 3.2
ng/mL; P < 0.005) and PTH (48.8± 15.1
vs. 37.2 ± 10.9 pg/mL; P <
0.0001) weredifferent in patients and controls. Patients were then
subdividedinto 2 groups: with (n = 8; group A) or without (n
= 24; groupB) subclinical hypercortisolism. PTH was higher
(P < 0.05)in group A than in group B and in both
groups than in controls(57.1 ± 13.6, 46.0 ± 14.8, and
37.2 ± 10.9pg/mL, respectively), and bone GLA protein was lower
in groupA than in group B and controls (3.8 ± 2.3, 7.5 ±
3.1,and 8.8 ± 3.2 ng/mL, respectively; P <
0.05). Serumtype I cross-linked C telopeptide and fasting urinary
deoxypyridinoline/creatininewere not different in the three groups.
BMD at each site waslower (P < 0.05) in group A
than in group B and controls.Bone mass and metabolism are altered in
AI patients with subclinicalhypercortisolism and should be taken into
account, therefore,when addressing the treatment of choice for these
patients.
This article has been cited by other articles:
C. Eller-Vainicher, V. Morelli, A. S. Salcuni, M. Torlontano, F. Coletti, L. Iorio, A. Cuttitta, A. Ambrosio, L. Vicentini, V. Carnevale, et al. Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?
Eur. J. Endocrinol.,
January 1, 2010;
162(1):
91 - 99.
[Abstract][Full Text][PDF]
I. Chiodini, V. Morelli, B. Masserini, A. S. Salcuni, C. Eller-Vainicher, R. Viti, F. Coletti, G. Guglielmi, C. Battista, V. Carnevale, et al. Bone Mineral Density, Prevalence of Vertebral Fractures, and Bone Quality in Patients with Adrenal Incidentalomas with and without Subclinical Hypercortisolism: An Italian Multicenter Study
J. Clin. Endocrinol. Metab.,
September 1, 2009;
94(9):
3207 - 3214.
[Abstract][Full Text][PDF]
B. Masserini, V. Morelli, S. Bergamaschi, F. Ermetici, C. Eller-Vainicher, A. M. Barbieri, M. A. Maffini, A. Scillitani, B. Ambrosi, P. Beck-Peccoz, et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma
Eur. J. Endocrinol.,
January 1, 2009;
160(1):
87 - 92.
[Abstract][Full Text][PDF]
P K Singh and H N Buch Adrenal incidentaloma: evaluation and management
J. Clin. Pathol.,
November 1, 2008;
61(11):
1168 - 1173.
[Abstract][Full Text][PDF]
I. Chiodini, M. L. Mascia, S. Muscarella, C. Battista, S. Minisola, M. Arosio, S. A. Santini, G. Guglielmi, V. Carnevale, and A. Scillitani Subclinical Hypercortisolism among Outpatients Referred for Osteoporosis
Ann Intern Med,
October 16, 2007;
147(8):
541 - 548.
[Abstract][Full Text][PDF]
R Nawar and D Aron Adrenal incidentalomas -- a continuing management dilemma
Endocr. Relat. Cancer,
September 1, 2005;
12(3):
585 - 598.
[Abstract][Full Text][PDF]
I. Chiodini, G. Guglielmi, C. Battista, V. Carnevale, M. Torlontano, M. Cammisa, V. Trischitta, and A. Scillitani Spinal Volumetric Bone Mineral Density and Vertebral Fractures in Female Patients with Adrenal Incidentalomas: The Effects of Subclinical Hypercortisolism and Gonadal Status
J. Clin. Endocrinol. Metab.,
May 1, 2004;
89(5):
2237 - 2241.
[Abstract][Full Text][PDF]
G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management
Endocr. Rev.,
April 1, 2004;
25(2):
309 - 340.
[Abstract][Full Text][PDF]
I. Chiodini, L. Tauchmanova, M. Torlontano, C. Battista, G. Guglielmi, M. Cammisa, A. Colao, V. Carnevale, R. Rossi, S. Di Lembo, et al. Bone Involvement in Eugonadal Male Patients with Adrenal Incidentaloma and Subclinical Hypercortisolism
J. Clin. Endocrinol. Metab.,
December 1, 2002;
87(12):
5491 - 5494.
[Abstract][Full Text][PDF]
L. Tauchmanova, R. Rossi, B. Biondi, M. Pulcrano, V. Nuzzo, E.-A. Palmieri, S. Fazio, and G. Lombardi Patients with Subclinical Cushing's Syndrome due to Adrenal Adenoma Have Increased Cardiovascular Risk
J. Clin. Endocrinol. Metab.,
November 1, 2002;
87(11):
4872 - 4878.
[Abstract][Full Text][PDF]
I. Chiodini, M. Torlontano, V. Carnevale, G. Guglielmi, M. Cammisa, V. Trischitta, and A. Scillitani Bone Loss Rate in Adrenal Incidentalomas: A Longitudinal Study
J. Clin. Endocrinol. Metab.,
November 1, 2001;
86(11):
5337 - 5341.
[Abstract][Full Text][PDF]
G. Osella, G. Reimondo, P. Peretti, A. Alì, P. Paccotti, A. Angeli, and M. Terzolo The Patients with Incidentally Discovered Adrenal Adenoma (Incidentaloma) Are Not at Increased Risk of Osteoporosis
J. Clin. Endocrinol. Metab.,
February 1, 2001;
86(2):
604 - 607.
[Abstract][Full Text]
M. Terzolo, S. Bossoni, A. Alí, M. Doga, G. Reimondo, G. Milani, P. Peretti, F. Manelli, A. Angeli, and A. Giustina Growth Hormone (GH) Responses to GH-Releasing Hormone Alone or Combined with Arginine in Patients with Adrenal Incidentaloma: Evidence for Enhanced Somatostatinergic Tone
J. Clin. Endocrinol. Metab.,
March 1, 2000;
85(3):
1310 - 1315.
[Abstract][Full Text]